×Close

Main navigation

Home
About
Technology
News & PR
For Patients
Contact
Careers

News and Press Releases

Back to News & PR

Nordic Life Sciences Interview: Valo Therapeutics CEO Paul Higham

Cover image

NLS Page 1

NLS Page 2

Other News

Read about what we're doing in Precision Oncology News

https://www.precisiononcologynews.com/Reprint-GW22015ValoTherapeutics

Scientific publication: Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in PeptiCRAd cancer vaccine platform

ValoTx is pleased to share a new publication in Molecular Therapy Oncolytics (2021 in press) from IVTLab and Valo Therapeutics on PeptiCRAd technology and our proprietary oncolytic adenovirus platform. A link to the paper can be found here Abstract Oncolytic viruses (OVs) have been shown to induce anti-cancer immunity and enhance cancer immunotherapies, such as immune checkpoint inhibitor therapies. OV therapies can be further improved by arming OVs with immunostimulatory molecules including various cytokines or chemokines. Here, we have developed

Valo Therapeutics Granted USA Patent for PeptiCRAd Technology in Cancer Immunotherapy

Helsinki, 24th November, 2020 Valo Therapeutics, the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced that the US Patent Office has granted US Patent No 10,799,568 on 13 October 2020, covering its lead PeptiCRAd platform technology. The patent covers the use of adenoviral vectors having tumor-specific peptides attached to the viral capsid, for stimulating targeted anti-tumor immune responses in cancer patients. Patents for PeptiCRAd technology have been previously granted in Europe (No 3145537) and in

© 2023 Valo Therapeutics LTD

Footer

Terms of Use
Privacy Statement

This website may contain forward-looking information which is provided to you on an “as is” basis without warranty of any kind as to the accuracy, completeness, currency, or reliability of any content available through this website. These risks and uncertainties include, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, clinical research, seeking regulatory approval and product commercialization, as well as the impact of competitive products, patents, product liability and third-party reimbursement risks associated with the pharmaceutical industry. Valo Therapeutics makes no representations or warranties that use of the website will be uninterrupted or error–free. You are responsible for verifying any information before relying on it. You are responsible for taking all necessary precautions to ensure that any content you may obtain from the website is free of viruses. This website may contain links to websites operated by other parties. The linked sites are not under the control of Valo Therapeutics, and Valo Therapeutics is not responsible for the content available on any other Internet sites linked to this website. Valo Therapeutics specifically disclaims any liability, whether based in contract, tort, strict liability or otherwise, for any direct, indirect, incidental, consequential, or special damages arising out of or in any way connected with access to or use of the website, even if Valo Therapeutics has been advised of the possibility of such damages, including but not limited to reliance by any party on any content obtained through the use of the website, or that arises in connection with mistakes or omissions in, or delays in transmission of, information to or from the user, interruptions in telecommunications connections to the website or viruses, whether caused in whole or in part by negligence, acts of God, telecommunications failure, theft or destruction of, or unauthorized access to the website, or related information or programs.